CSIMarket


Immunogen inc   (IMGN)
Other Ticker:  
 

Immunogen inc

IMGN's Fundamental analysis








Looking into Immunogen Inc growth rates, revenue grew by 637.72 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 63

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Immunogen Inc realized net income compared to net loss a year ago in III. Quarter 2023

More on IMGN's Growth


Immunogen Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 30.34 in trailing twelve-month period.
Company
-
PE TTM   
Industry
268.03
PE TTM    
Company's Price to Sales ratio is at 31.23.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.7.


More on IMGN's Valuation
 
 Total Debt (Millions $) 72
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,438,070
 Net Income/Employee (TTM) $ -367,610
 Receivable Turnover (TTM) 4.68
 Tangible Book Value (Per Share $) 1.95

Immunogen Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 30.34 in trailing twelve-month period.
Company
-
PE TTM   
Industry
268.03
PE TTM    
Company's Price to Sales ratio is at 31.23.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.7.

Immunogen Inc Price to Book Ratio is at 15.99 lower than Indusry Avg. of 1282.51. and higher than S&P 500 Avg. of 0.01

More on IMGN's Valuation

  Market Capitalization (Millions $) 8,981
  Shares Outstanding (Millions) 288
  Employees 200
  Revenues (TTM) (Millions $) 288
  Net Income (TTM) (Millions $) -74
  Cash Flow (TTM) (Millions $) 296
  Capital Exp. (TTM) (Millions $) -2
  Total Debt (Millions $) 72
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 1,438,070
  Net Income/Employee(TTM) $ -367,610
  Receivable Turnover Ratio (TTM) 4.68
  Tangible Book Value (Per Share $) 1.95

  Market Capitalization (Millions $) 8,981
  Shares Outstanding (Millions) 288
  Employees 200
  Revenues (TTM) (Millions $) 288
  Net Income (TTM) (Millions $) -74
  Cash Flow (TTM) (Millions $) 296
  Capital Exp. (TTM) (Millions $) -2


    IMGN's Profitability Comparisons
Immunogen Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 22.88 %.

Immunogen Inc net profit margin of 27.11 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 47 in Healthcare sector and number 500 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 5.7
  Total Debt to Equity (MRQ) 0.13
  Tangible Leverage Ratio (MRQ) 0.46
  Asset Turnover Ratio (TTM) 0.54
  Inventory Turnover Ratio (TTM) -



Immunogen Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 22.88 %.

Immunogen Inc net profit margin of 27.11 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 47 in Healthcare sector and number 500 in S&P 500.

More on IMGN's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com